Post-Acquisition Blow: 23andMe Buyer Hit with $47M Genetic Data Breach Fine

When Chrome Holding bought 23andMe's assets for $305 million, it hoped to reset the company's trajectory. Instead, the buyer has been ordered to pay $46.75 million to breach victims—a sum that redefines the risk calculus for biotech acquisitions, particularly those involving large repositories of sensitive genetic data. Even in bankruptcy, the true cost of poor data governance can follow the core asset.

The California bankruptcy court's ruling on July 7, 2026, requiring Chrome Holding to pay $46.75 million to victims of the 2023 23andMe data breach marks a pivotal moment in the intersection of genetic data privacy, corporate liability, and bankruptcy law. The ruling resolves the compensation phase of one of the most sensitive data breaches in history, where hackers accessed the detailed genetic and health profiles of 6.9 million individuals after compromising just 14,000 accounts through a technique known as credential stuffing. The settlement emerges from the ashes of 23andMe's Chapter 11 bankruptcy, which the company filed in early 2025—roughly 18 months after the breach became public—struggling under mounting legal costs, regulatory fines, and plummeting consumer trust.

“

When Chrome Holding bought 23andMe's assets for $305 million, it hoped to reset the company's trajectory.

The payout is not coming directly from 23andMe, which ceased to exist as an independent entity, but from Chrome Holding, the post-bankruptcy acquirer led by 23andMe co-founder and former CEO Anne Wojcicki. That acquisition, executed through a bankruptcy auction in mid-2025 for $305 million, was structured to salvage the company's core assets and technology while leaving behind the massive liability. The settlement order now carves out a significant sum—roughly 15% of the purchase price—to address the breach's fallout, raising critical questions about whether the bankruptcy system adequately accounts for consumer data privacy harms. Kroll Restructuring, the court‑appointed administrator, will manage the distribution, though the exact number of eligible victims and the per‑person payout remain undisclosed.

From an industry perspective, the fallout from the 23andMe breach has reshaped the direct‑to‑consumer genetic testing landscape. The compromise of genetic markers, health predispositions, and ancestry data exposed not only the 14,000 direct victims but also millions of their genetic relatives, thanks to the company's DNA Relatives feature. This amplification effect turned a relatively small account compromise into a population‑scale privacy crisis. Regulators swiftly responded: the UK Information Commissioner's Office (ICO) levied a £2.31 million fine, and the incident prompted broader scrutiny of how genetic data is stored, shared, and protected under regulations like GDPR and the evolving U.S. state privacy laws. The breach has been a cautionary tale for biotech, health‑IT, and genomics firms about the exponential liability when dealing with inherently identifiable and immutable personal data.

Financially, the $46.75 million settlement is among the larger per‑capita payouts in consumer data breach history when considering the 14,000 directly affected account holders, but it appears modest relative to the 6.9 million total profiles exposed. The use of bankruptcy to discharge or limit liability is a growing trend, but this ruling demonstrates that successors to assets can still be held accountable for inherited data‑related obligations. For investors and underwriters in biotech and digital health, the case introduces a new risk premium: the potential for massive, long‑tail liability from data breaches that can survive corporate restructuring and attach to asset buyers. The involvement of Kroll, a firm typically associated with corporate bankruptcy administration rather than data breach remediation, highlights the novel legal hybrid this case represents.